Summary of Clinical Use

Tosatoxumab is under clinical evaluation as an adjunctive therapy for patients being treated for ventilator-associated bacterial pneumonia (VAP) caused by S. aureus. Phase 1/2 (NCT01589185) results have been published [1] with tosatoxumab displaying clinical benefits and a favorable safety profile. A Phase 3 trial (NCT03816956) was completed in October 2022 (results yet to be published in a peer reviewed article).

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT03816956	Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301	Phase 3 Interventional	Aridis Pharmaceuticals, Inc.
NCT01589185	Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)	Phase 1/Phase 2 Interventional	Aridis Pharmaceuticals, Inc.		1